Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients

BACKGROUND: Following the PALOMA-3 study results, the combination of palbociclib, a CDK4/6 inhibitor, with fulvestrant, a selective estrogen receptor degrader, has become a standard therapy in women with estrogen receptor-positive (ER+) HER2-negative (HER2−) metastatic breast cancer (MBC). Palbocicl...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Breast Cancer Res
Autori principali: Darrigues, Lauren, Pierga, Jean-Yves, Bernard-Tessier, Alice, Bièche, Ivan, Silveira, Amanda Bartolini, Michel, Marc, Loirat, Delphine, Cottu, Paul, Cabel, Luc, Dubot, Coraline, Geiss, Romain, Ricci, Francesco, Vincent-Salomon, Anne, Proudhon, Charlotte, Bidard, François-Clément
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2021
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7937332/
https://ncbi.nlm.nih.gov/pubmed/33676547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-021-01411-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi